Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer|Bone Metastases in Subjects With Advanced Breast Cancer|Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Interventions: GENETIC: AMG 162 180 mg (SC) q 12 weeks|DRUG: IV Bisphosphonate q 4 weeks|GENETIC: AMG 162- 180 mg q 4 weeks
Sponsor: Amgen